The company's Biomea that is the lead program, icovamenib, is the first in the category of menin inhibitors directed to the treatment of both type 1 and type 2 diabetes that holds the potential to ...
Nothing in your spreadsheet is there by accident.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results